All News

Article

ACR 2024 - Day 1 Report

Jack Cush, MD Nov 16, 2024

ACR Convergence 2024 opened today with a full slate of presentations, posters and specialty meetings. The meeting began with a flip: the plenary sessions started at 9AM and the poster session began at 1030 AM. Below are some of the highlights from day one in Washington, DC.

In case you needed more encouragement for recombinant zoster vaccination in RA patients: it prevents herpes zoster episodes, in the real world. RA pts in KP system n=1926 vaccinated matched 1:3 with non-vaccinated - HZ reduced 60% - PHN reduced 88% #ACR24 ABST0977 @RheumNow https://t.co/BryBrlv9K5

https://x.com/drdavidliew/status/1858177833232998569/photo/1

#1330 🔬F-Calprotectin in Early RA ➡️ New-onset RA pts(n=104) had ⬆️ F-calprotectin vs controls(n=50)(71 v. 17µg/g; p<0.001) 🔑Higher F-calprotectin linked to ⬆️ DAS28 & NSAID use ⬇️levels @ 6 months Rx ❓Role of subclinical gut inflammation in early RA #ACR24 @RheumNow

GILZ is a negative regulator of the GC receptor, a potential steroid sparer target. Dr. Miceli et al identified an E3 ligase of GILZ "E3-X" where deficiency leads to ⬆️ GILZ & ⬇️ inflammation. More studies needed but a promising steroid sparer option. @Rheumnow #ACR24 abs1646 https://t.co/GuVMkgOTXT

#1165 📊 PBMCs of IIM patients with myocarditis(n=4) showed distinct gene expression v controls(n=4) v IIM alone(n=4)👇 💥 B-cell dysregulation may drive myocarditis in IIM 🎯Key immunological insights into🫀involvement in IIM #ACR24 @RheumNow @JuliePaikMD @jhrheumatology https://t.co/PceZUS929S

Is cognitive impairment in SLE driven by cell exhaustion or aging? Abstract 1514 shows that SLE patients with cognitive impairment had higher levels of CD8+ (cell exhaustion) and lower levels of cell senescence markers. @RheumNow #ACR24 https://t.co/SzxTQt3oNY

https://x.com/AkhilSoodMD/status/1858170733374939337/photo/1

#1350 🔬 Microbiome & RA: Impact on Disease Activity & Vascular Function ➡️ Salivary microbiome a/w arterial stiffness (AIx)(p 0.019) ➡️ Stool microbiome a/w DAS28-CRP(p 0.027) 🔴Key taxa👇identified for each; no common taxa for both disease activity & AIx. #ACR24 @RheumNow https://t.co/54Sumzzd27

https://x.com/CaoilfhionnMD/status/1858170984093925874/photo/1

#1326 🔬 Predicting Imminent Inflammatory Arthritis ➡️543 anti-CCP+ at-risk (high/low) tracked 🔑Predictors for IA in high-risk: 🔴EMS≥30min(OR 11) 🔴RF+(OR 6) 🔴US PD(OR 5) 🔴smJTC (OR 5) 🔑Predictors for IA in low risk: 🔴RF+(OR 8) 🔴Anti CCP >3xULN(OR 7) #ACR24 @RheumNow https://t.co/ou9HNcNb8X

https://x.com/CaoilfhionnMD/status/1858165950786474093/photo/1

Harkins @DrTrishHarkins et al. Novel diagnostic cytokines in treatment naive PMR. Elevations CXCL-9 (100%), MCP-1 (93%), IL-17A (83%), vs TNF (7%) and IL-6 (67%) @RheumNow #ACR24 Abstr#0881 https://t.co/DbYOn81QJH https://t.co/3eyre00D5d

The future use of a panel of immunological urinary biomarkers as a liquid biopsy for the management of lupus nephritis. Plenary Abstr#1642 @RheumNow #ACR24 https://t.co/waSRVd7FV7

https://x.com/synovialjoints/status/1858151875658359020/photo/1

This is very true. We showed a number of years ago that patients with gout have increased platelet activation at baseline, which then dramatically increases during flare. Treating gout properly may ameliorate this. #ACR24 @RheumNow https://t.co/VL8fy3ezjx https://t.co/9XdrG1NG9c

Stone et al. Phase 3 RCT B-cell depletion with CD19 targeting agent Inebilizumab in IgG4-RD. HR 0.13 (0.06, 0.28) for flare. @RheumNow #ACR24 Abstr#0775 https://t.co/Kd4Xmoc5e6 https://t.co/Al6gOA1F8K

How often should #scleroderma #ILD pts have #PFTs? 🤷‍♂️ Data from SENCIS RCT of SSc-ILD 25% worsened FVC by 6/12 Are we UNDER a ordering PFTs in an ILD #SSc population 👇 Because if worsening we would consider a change in background #immunesuppression @RheumNow #ACR24 #678 https://t.co/a9ybO3FwDd

https://x.com/Janetbirdope/status/1857849016001655085/photo/1

Interim analysis of a Phase 4 study of ARD (RA 25%, SLE 25%) patients shows recombinant herpes zoster vaccine(RZV) good safety profile, with no impact on disease activity (flare rates: 13.6% vs. 12.4%). Immunogenicity: 93% response in ARDs vs. 99% in controls. Rituximab & MMF… https://t.co/U3s48fLduX https://t.co/WTvD5shtXB

Pasoto et al. Holding MMF for 1 week after zoster vaccine (RZV) improves response with no increase in flare @RheumNow #ACR24 Abstr#0247 https://t.co/q757bMFp7I https://t.co/rwjz3q3MaO

#0066 🧬Epigenetics, Gut Microbiota & RA 🔬 110 RA patients v 110 controls 🦠 Collinsella abundance a/w DNA methylation changes (PRHOXNB, TBC1D22A) in RA, correlating with disease activity. 💡❔Role of gut microbiota & epigenetic markers as RA biomarkers #ACR24 @RheumNow https://t.co/yZn0KkRpE6

https://x.com/CaoilfhionnMD/status/1857816146025562514/photo/1

Planned to post so much more from #ACR24; my favorite slides from today will have to suffice. From the #BCRC Dr Monica Guma’s - diet and microbiome. Dr @NamrataRheum -a reminder that we are all aging. Dr Connie Weyand’s -metabolic checkpoints in RA T cells and macrophage. https://t.co/MtsheVsUEQ

#ACR24 Ab#0771 ARID5B - transcription factor controls pathologic inflammatory fibroblast ARID5B: RA risk locus on GWAS, also link to SLE, Graves Binds to histone editors to epigenetically regulate fibroblast state ARID5B deletion incr inflamm response, overexpr decr @RheumNow https://t.co/ebKnX1uTuO

Synovial fibroblast gene expression Neutron-4 - plays role in axonal outgrowth, affects pain-sensitive neurons May help explain pain in RA, possible targets Year in Review #ACR24 Bridges @RheumNow https://t.co/kpDVKh0C9O

Hot off the racks: The MITIGATE trial is the 1st RCT for IgG4-RD showing that Inebilizumab significantly reduced flare rates vs PbO by depleting CD19-targeted B cells Game changer? Year in review. @RheumNow #ACR24 @rheumarhyme @marklagacmd @idatan @ljdado https://t.co/CZvdrymIyr

Topics

All News

ACR 2024 - Day 1 Report

Do you get our email newsletter?